Incyte (INCY) investor relations material

Executive summary

• Strategy focuses on diversifying beyond a single product, with strong growth in hematology, oncology, and immunology portfolios, aiming for top-tier growth and durable revenue streams over the next five years.

• 2025 saw exceptional commercial and R&D performance, with net sales of $4.35 billion (20% YoY growth) and core business sales (excluding Jakafi) up 53% to $1.26 billion.

• Pipeline includes seven high-value assets with potential for over $10 billion in non-risk adjusted sales; 14 pivotal trials expected by end of 2026.

• Capital deployment is disciplined, focusing on strategic fit and financial return, with business development aimed at strengthening the portfolio.

Voting matters and shareholder proposals

• Shareholders will vote to elect eight directors, approve executive compensation (say-on-pay), and ratify Ernst & Young LLP as the independent auditor for 2026.

• Board recommends voting FOR all proposals.

Board of directors and corporate governance

• Board comprises a mix of experienced executives and independent directors, with strong expertise in biotech, finance, and governance.

• Four standing committees: Audit and Finance, Compensation, Nominating and Corporate Governance, and Science and Technology, all composed of independent directors.

• Annual board and committee evaluations, majority voting for directors, proxy access bylaw, and robust ethics codes in place.

• Board leadership separates Chair and CEO roles, with a strong focus on independence and regular executive sessions of independent directors.

• Succession planning and board refreshment are ongoing priorities, with an overboarding policy to ensure director engagement.